Clinical Trial Detail

NCT ID NCT03172754
Title Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications

renal cell carcinoma

Therapies

Axitinib + Nivolumab

Age Groups: adult senior

No variant requirements are available.